AVTX — Avalo Therapeutics Share News
0.000.00%
Last trade - 00:00- $399.54m
- $1.27m
- $0.06m
Brief: Avalo Reports Third Quarter Financial Results
Avalo Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Avalo Sells Economic Rights To Certain Assets For $5 Million
Avalo Therapeutics Inc expected to post a loss of $1.09 a share - Earnings Preview
Brief: Avalo Advances Btla Agonist Fusion Protein (Avtx-008) To Ind-Enabling Stage
U.S. RESEARCH ROUNDUP-Enovix, IRhythm Technologies, Paramount Global
Brief: Avalo Reports Q2 Loss Per Share Of $1.38
Avalo Therapeutics rises as dosing begins in rare disease trial
Brief: Avalo Therapeutics Announces First Patient Dosed In The Avtx-803 Pivotal Trial (Ladder) For The Treatment Of Leukocyte Adhesion Deficiency Type Ii (Lad Ii)
U.S. STOCKS ON THE MOVE-Scynexis, Sierra Wireless, CymaBay
U.S. STOCKS ON THE MOVE-PerkinElmer, Tesla, Scisparc
Avalo Therapeutics rises on $15 mln drug candidate transfer
Brief: Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (Camoteskimab) To Apollo Therapeutics
Avalo Therapeutics Inc expected to post a loss of $1.77 a share - Earnings Preview
Brief: Avalo Therapeutics Received Written Notification From Nasdaq Confirming That Co Had Regained Compliance
U.S. RESEARCH ROUNDUP- Bloom Energy, Northern Trust, West Pharmaceutical Services
Avalo Therapeutics drops after announcing reverse stock split
Brief: Avalo Therapeutics Announces One-For-Twelve Reverse Stock Split
Brief: Avalo Therapeutics Says First Patient Dosed in the Phase 2 Trial of AVTX-002 for Treatment of Non-Eosinophilic Asthma